2013
DOI: 10.1186/1757-2215-6-80
|View full text |Cite
|
Sign up to set email alerts
|

Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro

Abstract: BackgroundRNA interference technology has shown high therapeutic potential for cancer treatment. However, serum instability, poor tissue permeability and non-specific uptake of short interfering RNA (siRNA) limit its administration in vivo. To overcome these limitations and improve the specificity for ovarian cancer, we developed a targeted nanoparticle delivery system for siRNA. This system included follicle-stimulating hormone (FSH) β 33–53 peptide as a targeting moiety that specifically recognized FSH recep… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
21
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 21 publications
(22 citation statements)
references
References 38 publications
1
21
0
Order By: Relevance
“…Using the FSHR-targeting strategy, a chemotherapy drug (paclitaxel, PTX) 14, 15 or a gene silencing agent (small interfering RNA, siRNA) 16 was loaded into nanoparticles which were attached to binding domains of FSH (i.e. FSH33 or FSH β 81-95).…”
Section: Introductionmentioning
confidence: 99%
“…Using the FSHR-targeting strategy, a chemotherapy drug (paclitaxel, PTX) 14, 15 or a gene silencing agent (small interfering RNA, siRNA) 16 was loaded into nanoparticles which were attached to binding domains of FSH (i.e. FSH33 or FSH β 81-95).…”
Section: Introductionmentioning
confidence: 99%
“…As a segment of FSHβ chain, FSH 33-53 can bind to FSHR and was confirmed as an effective antagonist of FSH 17 . So FSH 33-53 was selected as a target unit to conjugate with drugs or drug anchors for delivery in FSHR expressed cancer cells 10 , 22 , 23 . But for the drawbacks of chemotherapeutics and nucleic acid in vivo , we modified the approach by conjugating FSH 33-53 with short peptides drugs.…”
Section: Discussionmentioning
confidence: 99%
“…Fluorescein-labeled generation 5 (G5) PAMAM dendrimers that are conjugated with FSH 33-53 significantly enhances the uptake of dendrimers and down-regulation of Survivin, an anti-apoptotic protein, in FSHR-expressing OVCAR-3 cells, but not in SKOV-3 cells which don't express FSHR 22 . Also, FSH 33 -G-NP, FSHβ 33-53 peptide-conjugated gro-α siRNA-loaded PEG-PEI nanoparticles, significantly silences the expression of oncogene gro-α in ovarian cancer cell, ES-2 and consequently suppresses the proliferation, migration and invasion of the cell greatly in comparison to G-NP alone 23 .…”
Section: Introductionmentioning
confidence: 98%
“…Both FSH and LH ligands bind receptors present on the normal ovary as well as on ovarian cancer cells, and peptide fragments of these hormone ligands have been used to target NPs. Hong and colleagues examined the efficacy of NPs composed of FSH β (33–55)-PEG-PEI and the cytokine si Gro-α against ovarian tumor cells [ 137 ]. Compared to the untargeted NP in complex to si Gro-α , the numbers of cells and migration distance of cells were reduced by about 35% and 75%, respectively.…”
Section: Targeting Tumor Cellsmentioning
confidence: 99%